Clinical trial · Interventional
Clinical Study of Targeted Cryoablation Therapy in the Treatment of Hepatic Carcinoma
Evaluating the Safety and Efficacy of Targeted Cryoablation Therapy in the Treatment of Hepatic Carcinoma
NCT02969096CI-TRIAL-00024850unknownPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to evaluate the safety and efficacy of targeted cryoablation therapy for hepatic carcinoma.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Liver Neoplasms | Liver Neoplasm | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Targeted Cryoablation Therapy | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Targeted Cryoablation Therapy
- description
- liver cancer patients received targeted cryoablation therapy.
- interventionNames
- Procedure: Targeted Cryoablation Therapy
Primary outcomes (1)
- measure
- Rate of complete tumor ablation
- timeFrame
- Up to 4 weeks post surgery
Secondary outcomes (1)
- measure
- Adverse Events
- timeFrame
- Up to 4 weeks post surgery
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 75 Years
Show eligibility criteria text
Inclusion Criteria: * Diagnosis of liver cancer based on histology or the current accepted radiological measures. * Single Tumor size ≤5.0 cm in greatest diameter, or multiple tumor number≤3 and each tumor size≤ 3cm. * Life expectancy: Greater than 3 months. * Patients' liver function is Child-pugh A or B. * Ability to understand the study protocol and a willingness to sign a written informed consent document. * Unable to receive operative surgery. Exclusion Criteria: * Patients with other primary tumor except liver cancer. * History of coagulation disorders or anemia.
References
Publications (0)
Data not yet available
No reference posted for this study.